Oxford Cancer Biomarkers technologies licensed in China
19th April 2017
Spinout Oxford Cancer Biomarkers announces strategic collaboration with My-BioMed Biotechnology Co. Ltd, providing precision medicine to clinicians and patients in China
Oxford Cancer Biomarkers Ltd, a 2011 spinout from Oxford University that is developing tests to allow medicines to be personalised for the benefit of the cancer patient, has announced a strategic collaboration with My-BioMed Biotechnology Co. Ltd. based in Ningbo, Zhejiang, China.
The collaboration will allow OCB’s suite of precision oncology In Vitro Diagnostic tests to be rolled out across the Peoples Republic of China, and the partnership includes a licencing deal that will allow My-BioMed Biotechnology Ltd to access OCB’s ColoTox, ColoProg and ColoPredict technologies and to drive uptake across the Peoples Republic of China via a purpose built biomedical laboratory in Ningbo Meishan FTZ.